


This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

### Stereospecific Synthesis and Antiviral Activities of $\beta$ -L-2',3'-Dideoxy-5-chloropyrimidine Nucleoside Derivatives

C. Pierra<sup>a</sup>; G. Gosselin<sup>a</sup>; J-P. Sommadossi<sup>b</sup>; A. Faraj<sup>b</sup>; E. De Clercq<sup>c</sup>; J. Balzarini<sup>c</sup>; J-L. Imbach<sup>a</sup>

<sup>a</sup> Laboratoire de Chimie Bioorganique, UMR CNRS 5625, Université de Montpellier II, Montpellier Cedex 5, France <sup>b</sup> Department of Pharmacology, University of Alabama at Birmingham, Birmingham, AL, USA <sup>c</sup> Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium

**To cite this Article** Pierra, C. , Gosselin, G. , Sommadossi, J-P. , Faraj, A. , De Clercq, E. , Balzarini, J. and Imbach, J-L.(1999) 'Stereospecific Synthesis and Antiviral Activities of  $\beta$ -L-2',3'-Dideoxy-5-chloropyrimidine Nucleoside Derivatives', *Nucleosides, Nucleotides and Nucleic Acids*, 18: 4, 643 – 644

**To link to this Article:** DOI: 10.1080/15257779908041526

**URL:** <http://dx.doi.org/10.1080/15257779908041526>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

**STEREOSPECIFIC SYNTHESIS AND ANTIVIRAL  
ACTIVITIES OF  $\beta$ -L-2',3'-DIDEOXY-5-CHLOROPYRIMIDINE  
NUCLEOSIDE DERIVATIVES**

C. Pierra,<sup>1</sup> G. Gosselin,<sup>1\*</sup> J.-P. Sommadossi,<sup>2</sup> A. Faraj,<sup>2</sup> E. De Clercq,<sup>3</sup> J.  
Balzarini<sup>3</sup> and J.-L. Imbach<sup>1</sup>

<sup>1</sup>Laboratoire de Chimie Bioorganique, UMR CNRS 5625, Université de Montpellier II,  
Montpellier Cedex 5, France, <sup>2</sup>Department of Pharmacology, University of Alabama at  
Birmingham, Birmingham, AL 35294-0019, USA, <sup>3</sup>Rega Institute for Medical Research,  
Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.


**ABSTRACT:** Several 5-chlorouracil and 5-chlorocytosine  $\beta$ -L-dideoxynucleosides were stereospecifically synthesized and their activities against human immunodeficiency virus (HIV) and hepatitis B virus (HBV) were examined in cell culture.

Pandemic morbidity and mortality due to HIV and HBV account for intensive efforts in discovering effective agents against these viruses. Among the nucleoside analogs which have been shown to possess potent antiviral activity, 2',3'-dideoxy-3'-fluorothymidine (FddT) had been described as the most effective inhibitor of HIV-1 replication in various cellular systems albeit to the detriment of considerable cytotoxic effects.<sup>1</sup> Subsequently, several 5-halogeno derivatives of FddU have been synthesized,<sup>2</sup> and among them, 2',3'-dideoxy-3'-fluoro-5-chlorouridine (FddCIU) emerged as a selective anti-HIV agent.<sup>3,4</sup>

Recently, L-nucleosides have proven to be of great importance as anti-HIV<sup>5</sup> and anti-HBV agents,<sup>6</sup> with a number of these compounds showing promising activity when compared to their corresponding D-enantiomers. Consequently, we decided to synthesize and to study the  $\beta$ -L-enantiomer of FddCIU and its *t*-butylSATE pronucleotide,<sup>7</sup> as well as several other 5-chloropyrimidine  $\beta$ -L-nucleoside derivatives ranging from the 5-chlorouracil to the 5-chlorocytosine series (FIG.).

All the presently reported (and hitherto unknown)  $\beta$ -L-nucleosides and pronucleotides were evaluated for their inhibitory effects against HIV and HBV. However, none of these compounds showed significant antiviral activity, except for 2',3'-dideoxy- $\beta$ -L-5-chlorocytidine and 2',3'-dideoxy-2',3'-didehydro- $\beta$ -L-5-chlorocytidine which were

endowed with some anti-HBV activity ( $EC_{50} = 10$  and  $5 \mu M$ , respectively ;  $CC_{50} > 200 \mu M$  in Hep-G2 cells). Unfortunately, no enhancement of the antiviral activities of the two *t*-butylSATE  $\beta$ -L-pronucleotides, in comparison with their parent nucleosides, was observed.



- FIG. -

## ACKNOWLEDGEMENTS

This work was supported by grants from the Agence Nationale de Recherche sur le SIDA (ANRS, France).

## REFERENCES

- 1- Herdewijn, P.; Van Aerschot, A.; Balzarini, J. and De Clercq, E. *Med. Chem. Res.*, **1991**, *1*, 9-19.
- 2- Balzarini, J.; Van Aerschot, A.; Pauwels, R.; Baba, M.; Schols, D.; Herdewijn, P. and De Clercq, E. *Mol. Pharmacol.*, **1989**, *35*, 571-577.
- 3- Van Aerschot, A.; Everaert, D.; Balzarini, J.; Augustyns, K.; Jie, L.; Janssen, G.; Peeters, O.; Blaton, N.; De Ranter, C.; De Clercq, E. and Herdewijn, P. *J. Med. Chem.*, **1990**, *33*, 1833-1839.
- 4- Daluge, S.M.; Purifoy, D. J. M.; Savina, P. M.; St Clair, M. H.; Parry, N. R.; Dev, I. K.; Novak, P.; Ayers, K. M.; Reardon, J. E.; Roberts, G. B.; Fyfe, J. A.; Blum, M. R.; Averett, D. R.; Dornsife, R. E.; Domin, B. A.; Ferone, R.; Lewis, D. A. and Krenitsky, T. A. *Antimicrob. Agents Chemother.*, **1994**, *38*, 1590-1603.
- 5- Gosselin, G.; Schinazi, R.F.; Sommadossi, J.-P.; Mathé, C.; Bergogne, M.-C.; Aubertin, A.-M.; Kirn, A. and Imbach, J.-L. *Antimicrob. Agents Chemother.*, **1994**, *38*, 1292-1297.
- 6- Schinazi, R. F.; Gosselin, G.; Faraj, A.; Korba, B. E.; Liotta, D. C.; Chu, C. K.; Mathé, C.; Imbach, J.-L. and Sommadossi, J.-P. *Antimicrob. Agents Chemother.*, **1994**, *38*, 2172-2174.
- 7- Lefebvre, I.; Périgaud, C.; Pompon, A.; Aubertin, A.-M.; Girardet, J.-L.; Kirn, A.; Gosselin, G. and Imbach, J.-L. *J. Med. Chem.*, **1995**, *38*, 3941-3950.